Remove Coronary Artery Disease Remove Myocardial Infarction Remove Plaque
article thumbnail

Vessel-Level Coronary Atherosclerotic Plaque Activity Predicts Myocardial Infarction Risk

Cardiology Update

Coronary artery disease remains a leading cause of morbidity and mortality worldwide. Recent research has illuminated the role of total coronary atherosclerotic plaque activity across the entire coronary arterial tree in predicting patient-level clinical outcomes. 3.72; P = 0.013).

article thumbnail

Trial Results: Low-Dose Colchicine HelpsTreat Cardiovascular Disease

DAIC

mg reduces the risk of major adverse cardiovascular events (MACE) and supports its use in the treatment of cardiovascular disease. mg)has potential to directly reduce inflammation, which plays a substantial role in the formation and progression of atherosclerotic plaque leading to heart disease, said Matthew J. Budoff, M.D.,

52
article thumbnail

Safety and possible anti-inflammatory effect of paclitaxel associated with LDL-like nanoparticles (LDE) in patients with chronic coronary artery disease: a double-blind, placebo-controlled pilot study

Frontiers in Cardiovascular Medicine

We investigated whether treatment with LDE-paclitaxel changes plaque progression by coronary CT angiography and is safe in patients with chronic coronary artery disease. Analysis of inflammatory biomarkers and coronary CTA was also performed at baseline and 4 weeks after treatment.

article thumbnail

7 Things You Can Do To Reduce Your Risk Even If You Already Have Heart Disease.

Dr. Paddy Barrett

A common feedback I get is that people with existing coronary artery disease feel like it doesn’t apply to them. Arguably, applying the principles of prevention offers more bang for buck in the short term for people WITH coronary artery disease than those without coronary artery disease.

article thumbnail

Exosomal circSCMH1/miR-874 ratio in serum to predict carotid and coronary plaque stability

Frontiers in Cardiovascular Medicine

Background To investigate the correlation between lg (circSCMH1/miR-874) and acute coronary syndrome (ACS), acute myocardial infarction (AMI), and carotid plaque stability. Methods 701 patients were divided into stable coronary artery disease (SCAD), ACS, and control groups.

Plaque 59
article thumbnail

HeartFlow Announces Revolutionary Five-Year Data Demonstrating a 63 Percent Mortality Reduction with FFRCT-Guided Care in PAD Patients

DAIC

1 Atherosclerosis is a systemic disease that affects multiple vascular regions and is particularly severe in PAD patients, where up to 80 percent suffer from concurrent coronary artery disease (CAD), historically linked with a mortality rate exceeding 50 percent within five years.

article thumbnail

Medicare Administrative Contractors to Extend Coverage of AI Coronary Plaque Analysis

DAIC

15, 2024 – Elucid has announced that four of the seven Medicare Administrative Contractors (MACs) will extend coverage for AI-enabled quantitative coronary plaque analysis, including its FDA-cleared PlaqueIQ image analysis software, beginning Nov. In the United States, one person dies every 33 seconds from cardiovascular disease.

Plaque 52